Exhibit 99.1

                              N E W S  R E L E A S E

               Fast Track Designation Approved by FDA for Aphton's
           G17DT Anti-Gastrin Immunogen for Pancreatic Cancer Therapy

                               September 23, 2002

Miami, FL - Aphton Corporation (NASDAQ:  APHT) - Aphton announced today that the
U.S. FDA has reviewed  Aphton's request for Fast Track designation for its G17DT
(anti-gastrin) immunogen under its Investigational New Drug Application (IND) to
treat pancreatic cancer patients together with the chemotherapy  gemcitabine and
concluded  that it  meets  the  criteria  for  Fast  Track  designation.  Aphton
announced on August 19, 2002, that it had filed an application  with the FDA for
this designation.

Fast Track is a formal  mechanism to interact with the FDA using approaches that
are available to all applicants for marketing claims. The benefits of Fast Track
include scheduled  meetings to seek FDA input into development plans, the option
of  submitting a New Drug  Application  in sections  rather than all  components
simultaneously,  and the  option  of  requesting  evaluation  of  studies  using
surrogate endpoints.  The Fast Track designation is intended for the combination
of a  product  and a  claim  that  addresses  an  unmet  medical  need,  but  is
independent of the FDA's priority review and accelerated approval mechanisms.

It is estimated that approximately 88,000 new cases of pancreatic cancer will be
diagnosed  in the US and  Europe  this  year.  The  prognosis  for most of these
patients is very poor. The great  majority of patients have advanced  disease at
the time of diagnosis and are considered  incurable,  with a very short survival
time. Surgery, when possible, and chemotherapy are the primary treatment options
currently available,  but have shown only very limited benefit.  Aphton believes
that its  anti-gastrin  targeted  immunotherapy  approach  has the  potential to
extend patient survival significantly, without adding toxicity.

Aphton is conducting one Phase III and three Phase II clinical trials.  Aphton's
anti-gastrin  targeted therapy induces  antibodies in patients that bind to both
gastrin 17 and gly-gastrin and remove them from circulation before they can bind
to the cancer  cell and  initiate  cell  growth.  (Aphton  believes  this is the
optimum  method  for  achieving  "growth  factor  inhibition.")  Gastrin  17 and
gly-gastrin  are  believed  to be  central  growth  factors,  or the  initiating
signals, for cell growth, cell proliferation and metastasis (spread) in gastric,
i.e. stomach, pancreatic, esophageal, colorectal and other gastrointestinal (GI)
system cancers. This signaling program is accomplished by gastrin binding to the
large numbers of gastrin  receptors which appear, de novo, in the great majority
of  cases,  on tumor  cell  surfaces  throughout  the  gastrointestinal  system.
Interrupting  this process by


<PAGE>
immunizing  the patient  with  Aphton's  anti-gastrin  immunogen  is a precisely
"targeted" immunotherapy. This specificity of targeting only cancer cells occurs
because gastrin is not normally  secreted and gastrin receptors are not normally
found on "healthy" cells in the GI system, unless they are malignant,  or on the
path to malignancy (except for cells involved with normal acid secretion).

Recent  findings  have shown that  inhibiting  gastrin  not only  inhibits  cell
growth,  proliferation  and metastasis  directly,  but also "unblocks" a central
pathway leading to cell-suicide  (apoptosis).  This tilts the balance, from cell
growth, to cell suicide. This effect is amplified  synergistically when Aphton's
drug is given  together with a  chemotherapeutic.  Gastrin also  stimulates  the
secretion and expression of other important  growth factors and receptors within
and on the  surfaces  of the  cancer  cells  involved  in tumor  growth.  Hence,
inhibiting  gastrin inhibits all of the foregoing factors  contributing to tumor
growth  and  spread,  while  simultaneously  opening a central  pathway  to cell
suicide.  Aphton's  anti-gastrin targeted therapy adds a biological dimension to
the treatment of gastrointestinal cancers.

Aphton Corporation is a biopharmaceutical  company developing products using its
innovative  targeted  immunotherapy  technology for  neutralizing  hormones that
participate  in  gastrointestinal  system  and  reproductive  system  cancer and
non-cancer  diseases;  and the  prevention  of  pregnancy.  Aphton has strategic
alliances  with Aventis  (NYSE:  AVE) for treating  gastrointestinal  system and
other  cancers with G17DT in North  America and Europe;  GlaxoSmithKline  (NYSE:
GSK) for  reproductive  system cancer and  non-cancer  diseases  worldwide;  and
others.

Except for the historical  information  herein, the matters discussed herein are
forward-looking  statements that involve a number of risks and uncertainties and
are not a guarantee of future performance. Future results may vary significantly
based on a  number  of  factors  including,  but not  limited  to,  intellectual
property  risks,  risks in regulatory and market  acceptance of new products and
continuing  demand for same,  the impact of  competitive  products  and pricing,
changing  economic  conditions  and other risk  factors that are inherent in the
drug development process and the company's business including those set forth in
Aphton's  most recent 10-K and other  filings with the  Securities  and Exchange
Commission. It is not possible to predict or identify all such risk factors that
could cause actual  results to differ from expected or historical  results.  The
company's actual results could differ from these forward-looking  statements and
the company  undertakes  no obligation  to update  publicly any  forward-looking
statement.

Contact: Aphton Corporation; Investor Relations, J.L. Whitmore, 305-374-7338.

                                      -2-